Veterinary services company CVS (CVSG:AIM) saw its shares jump 13% on 1 May in response to the release of the CMA’s (Competition and Markets Authority) working paper on potential remedies for the £6.3 billion vet market which it has been investigating over the last year.

The latest price move takes the gain since the start of 2025 to 54%, making CVS one of the best-performing stocks in the UK this year.

The share price reaction reflects the relatively benign set of potential remedies drawn up by the CMA, which analysts expect to have a low- to medium-level impact on the business.

It is worth noting the regulator has not yet come to an overall view on whether or not the industry suffers from unfair competition or excessive pricing, or indeed whether remedies will be required at all.

The authority has asked companies for feedback from its current working paper which runs to the end of May. The next working paper will address possible excessive profitability before a provisional decision is made in July. 

‹ Previous2025-05-08Next ›